Placebo Controlled Trial of NRX-101 for the Maintenance of Stabilization From Acute Suicidal Ideation and Behavior in Bipolar Depression (STABIL-B)

Trial Profile

Placebo Controlled Trial of NRX-101 for the Maintenance of Stabilization From Acute Suicidal Ideation and Behavior in Bipolar Depression (STABIL-B)

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Cycloserine/lurasidone (Primary)
  • Indications Bipolar depression; Suicidal ideation
  • Focus Registrational; Therapeutic Use
  • Sponsors NeuroRX
  • Most Recent Events

    • 23 Mar 2017 Planned initiation date changed from 1 Jan 2017 to 15 Jun 2017.
    • 04 Jan 2017 According to a NeuroRx media release, company is now enrolling study sites for its clinical trial of NRX-101.
    • 04 Jan 2017 According to a NeuroRx media release, company has received FDA clearance to proceed with this trial under an IND application.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top